Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics, 2023
2023 · External reference
10.1016/s0140-6736(20)30974-0
10.1016/s0140-6736(20)30974-0 · External reference
10.1053/j.gastro.2023.02.012
10.1053/j.gastro.2023.02.012 · External reference
Recent trends in the incidence and survival of stage 1A pancreatic cancer: a surveillance, epidemiology, and end results analysis
10.1093/jnci/djaa004 · 2020 · External reference
10.1016/j.drup.2015.10.002
10.1016/j.drup.2015.10.002 · External reference
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
10.1200/jco.1997.15.6.2403 · 1997 · External reference
Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies
10.1016/j.canlet.2023.216382 · 2023 · External reference
10.1152/ajpcell.00331.2022
10.1152/ajpcell.00331.2022 · External reference
Follicular helper T cells remodel the immune microenvironment of pancreatic cancer via secreting CXCL13 and IL-21
2021 · External reference
Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade
10.1186/s13046-022-02307-3 · 2022 · External reference
CC Chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands
10.3390/ijms21207619 · 2020 · External reference
10.1126/sciadv.aax4690
10.1126/sciadv.aax4690 · External reference
10.1093/carcin/bgq265
10.1093/carcin/bgq265 · External reference
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma
10.1158/1078-0432.ccr-10-3186 · 2012 · External reference
Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell-NK cell axis in murine hepatocellular carcinoma model
10.1016/j.jhep.2022.03.011 · 2022 · External reference
10.1158/2326-6066.cir-14-0235
10.1158/2326-6066.cir-14-0235 · External reference
10.1016/j.cytogfr.2019.11.001
10.1016/j.cytogfr.2019.11.001 · External reference
SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine
2022 · External reference
Enhancing web search result clustering model based on multiview multirepresentation consensus cluster ensemble (mmcc) approach
10.1371/journal.pone.0245264 · 2021 · External reference
Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer
10.1038/s41419-023-06313-x · 2023 · External reference
10.1016/j.celrep.2016.12.019
10.1016/j.celrep.2016.12.019 · External reference
10.1158/0008-5472.can-18-0689
10.1158/0008-5472.can-18-0689 · External reference
Profiling tumor infiltrating immune cells with CIBERSORT
10.1007/978-1-4939-7493-1_12 · 2018 · External reference
Identification of novel subtypes based on ssGSEA in immune-related prognostic signature for tongue squamous cell carcinoma
10.1002/cam4.4341 · 2021 · External reference
Cell-type enrichment analysis of bulk transcriptomes using xCell
10.1007/978-1-0716-0327-7_19 · 2020 · External reference
xCell: digitally portraying the tissue cellular heterogeneity landscape
10.1186/s13059-017-1349-1 · 2017 · External reference
TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells
10.1158/0008-5472.can-17-0307 · 2017 · External reference
TIMER2.0 for analysis of tumor-infiltrating immune cells
10.1093/nar/gkaa407 · 2020 · External reference
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data
10.1186/s13073-019-0638-6 · 2019 · External reference
Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq
10.1016/bs.mie.2019.05.056 · 2020 · External reference
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
10.1186/s13059-016-1070-5 · 2016 · External reference
Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data
10.7554/elife.26476 · 2017 · External reference
10.1158/2326-6066.cir-18-0436
10.1158/2326-6066.cir-18-0436 · External reference
Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR
10.2214/ajr.09.4110 · 2010 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
Radiographic and serologic predictors of pathologic major response to preoperative therapy for pancreatic cancer
10.1097/sla.0000000000003442 · 2021 · External reference
Response and Survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma
10.1001/jamasurg.2020.2286 · 2020 · External reference
DrugBank: a comprehensive resource for in silico drug discovery and exploration
10.1093/nar/gkj067 · 2006 · External reference
10.1146/annurev-pathmechdis-031621-024600
10.1146/annurev-pathmechdis-031621-024600 · External reference
Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
10.1186/s13046-019-1313-x · 2019 · External reference
10.1002/cam4.3627
10.1002/cam4.3627 · External reference
10.1007/s13167-023-00327-3
10.1007/s13167-023-00327-3 · External reference
Machine learning-derived identification of prognostic signature for improving prognosis and drug response in patients with ovarian cancer
2023 · External reference
Electronic address, a.a.d.h.e. and N. cancer genome atlas research, integrated genomic characterization of pancreatic ductal adenocarcinoma
10.1016/j.ccell.2017.07.007 · 2017 · External reference
10.1038/s41575-019-0109-y
10.1038/s41575-019-0109-y · External reference
10.1111/imr.13147
10.1111/imr.13147 · External reference
10.1016/j.cell.2023.09.020
10.1016/j.cell.2023.09.020 · External reference
The complement C3a and C3a receptor pathway in kidney diseases
10.3389/fimmu.2020.01875 · 2020 · External reference
10.1016/j.semcdb.2017.11.023
10.1016/j.semcdb.2017.11.023 · External reference
Cntnap4 partial deficiency exacerbates alpha-synuclein pathology through astrocyte-microglia C3-C3aR pathway
10.1038/s41419-023-05807-y · 2023 · External reference
C3a-C3aR signaling promotes breast cancer lung metastasis via modulating carcinoma associated fibroblasts
10.1186/s13046-019-1515-2 · 2020 · External reference
Complement C3a activates astrocytes to promote medulloblastoma progression through TNF-alpha
10.1186/s12974-022-02516-9 · 2022 · External reference
10.1016/j.cell.2023.02.014
10.1016/j.cell.2023.02.014 · External reference
10.1172/jci90962
10.1172/jci90962 · External reference
Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors
10.1053/j.gastro.2006.07.011 · 2006 · External reference
Complement component 3 is regulated by TWIST1 and mediates epithelial-mesenchymal transition
10.4049/jimmunol.1501886 · 2016 · External reference
The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL
10.1038/s41586-019-1608-2 · 2019 · External reference
The complement C3a-C3a receptor axis regulates epithelial-to-mesenchymal transition by activating the ERK pathway in pancreatic ductal adenocarcinoma
10.21873/anticanres.15587 · 2022 · External reference
The combination of radiotherapy and complement C3a inhibition potentiates natural killer cell functions against pancreatic cancer
10.1158/2767-9764.crc-22-0069 · 2022 · External reference
Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approach
2022 · External reference
10.1016/j.semcdb.2017.11.023
10.1016/j.semcdb.2017.11.023 · External reference
Targeting the complement pathway in malignant glioma microenvironments
2021 · External reference
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
10.1186/s12882-021-02470-3 · 2021 · External reference
A case of gemcitabine-induced thrombotic microangiopathy treated with ravulizumab in a patient with stage IV pancreatic cancer
2021 · External reference
Dynamic EMT: a multi-tool for tumor progression
10.15252/embj.2021108647 · 2021 · External reference
Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approach
2022 · External reference
Role of the complement system in the tumor microenvironment
10.1186/s12935-019-1027-3 · 2019 · External reference
10.1038/ni.1655
10.1038/ni.1655 · External reference
Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer
10.1080/00365520410005603 · 2004 · External reference
